Q-omics provides the consensus-scored PCDHGA8 profile across patient tissues and cancer cell-line models. PCDHGA8 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PCDHGA8 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, PCDHGA8 RNA expression shows 17,611 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, THCA, and THYM as cancer lineages where PCDHGA8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHGA8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHGA8 survival associations across molecular data types. PCDHGA8 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHGA8 RNA expression–survival associations across cancer types. High PCDHGA8 expression shows unfavorable associations in BLCA, LUSC, BRCA, ACC and CHOL, but favorable associations in UCS. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify BLCA as the clearest survival context for PCDHGA8 RNA expression.
This table summarizes PCDHGA8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PCDHGA8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHGA8 shows lower tumor expression in THCA and LUSC and higher tumor expression in CHOL, BRCA, LIHC and LUAD. The THCA box plot shows higher PCDHGA8 RNA expression in normal versus tumor tissue (log2 FC = −0.098, t-test p < 0.001).
This table shows molecular features associated with PCDHGA8 in patient tissues and cancer cell lines. In patient samples, PCDHGA8 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHGA8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and NCI60_ALL.
